High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal

Peter Bartenstein, Elisa Caballero Calabuig, Carlo Ludovico Maini, Renzo Mazzarotto, M. Angustias Muros De Fuentes, Thorsten Petrich, Fernando José Cravo Rodrigues, Juan Antonio Vallejo Casas, Federica Vianello, Michela Basso, Marcelino Gómez Balaguer, Alexander Haug, Fabio Monari, Raquel Sánchez Vaňó, Rosa Sciuto, James Magner

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Few data exist on using thyrotropin alfa (recombinant human thyroid-stimulating hormone [rhTSH]) with radioiodine for thyroid remnant ablation of patients who have T4 primary tumors (invasion beyond the thyroid capsule). Methods: A retrospective chart review protocol at nine centers in Europe was set up with special waiver of need for informed consent, along with a careful procedure to avoid selection bias when enrolling patients into the database. Data on 144 eligible patients with T4 tumors were collected (T4, N0-1, M0-1; mean age 49.7 years; 65% female; 88% papillary cancer). All had received 131I remnant ablation following TSH stimulation with rhTSH or thyroid hormone withdrawal (THW) since January 2000 (rhTSH n=74, THW n=70). The primary endpoint was based on evaluation of diagnostic radioiodine scan thyroid bed uptake more than six months after the ablation procedure, while stimulated serum Tg was a secondary endpoint. Safety was evaluated within 30 days after rhTSH or 131I. Results: Successful ablation judged by scan was achieved in 65/70 (92.9%) of rhTSH and in 61/67 (91.0%) of THW patients; the success rates were comparable, since noninferiority criteria were met. Although some patients in the initial cohort had tumor in cervical nodes and metastases, considering all evaluable patients regardless of various serum anti-Tg antibody assessments, the stimulated Tg was 30 IU/mL were excluded, the stimulated Tg was

Original languageEnglish
Pages (from-to)480-487
Number of pages8
JournalThyroid
Volume24
Issue number3
DOIs
Publication statusPublished - Mar 1 2014

Fingerprint

Thyrotropin
Thyroid Hormones
Thyroid Neoplasms
Neoplasms
Thyroid Gland
Thyrotropin Alfa
Selection Bias
Informed Consent
Serum
Capsules
Anti-Idiotypic Antibodies
Databases
Neoplasm Metastasis
Safety

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Bartenstein, P., Calabuig, E. C., Maini, C. L., Mazzarotto, R., De Fuentes, M. A. M., Petrich, T., ... Magner, J. (2014). High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. Thyroid, 24(3), 480-487. https://doi.org/10.1089/thy.2013.0157

High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. / Bartenstein, Peter; Calabuig, Elisa Caballero; Maini, Carlo Ludovico; Mazzarotto, Renzo; De Fuentes, M. Angustias Muros; Petrich, Thorsten; Rodrigues, Fernando José Cravo; Vallejo Casas, Juan Antonio; Vianello, Federica; Basso, Michela; Balaguer, Marcelino Gómez; Haug, Alexander; Monari, Fabio; Vaňó, Raquel Sánchez; Sciuto, Rosa; Magner, James.

In: Thyroid, Vol. 24, No. 3, 01.03.2014, p. 480-487.

Research output: Contribution to journalArticle

Bartenstein, P, Calabuig, EC, Maini, CL, Mazzarotto, R, De Fuentes, MAM, Petrich, T, Rodrigues, FJC, Vallejo Casas, JA, Vianello, F, Basso, M, Balaguer, MG, Haug, A, Monari, F, Vaňó, RS, Sciuto, R & Magner, J 2014, 'High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal', Thyroid, vol. 24, no. 3, pp. 480-487. https://doi.org/10.1089/thy.2013.0157
Bartenstein, Peter ; Calabuig, Elisa Caballero ; Maini, Carlo Ludovico ; Mazzarotto, Renzo ; De Fuentes, M. Angustias Muros ; Petrich, Thorsten ; Rodrigues, Fernando José Cravo ; Vallejo Casas, Juan Antonio ; Vianello, Federica ; Basso, Michela ; Balaguer, Marcelino Gómez ; Haug, Alexander ; Monari, Fabio ; Vaňó, Raquel Sánchez ; Sciuto, Rosa ; Magner, James. / High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. In: Thyroid. 2014 ; Vol. 24, No. 3. pp. 480-487.
@article{6e5ff5c34d3c419da99d41eec4ad812d,
title = "High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal",
abstract = "Background: Few data exist on using thyrotropin alfa (recombinant human thyroid-stimulating hormone [rhTSH]) with radioiodine for thyroid remnant ablation of patients who have T4 primary tumors (invasion beyond the thyroid capsule). Methods: A retrospective chart review protocol at nine centers in Europe was set up with special waiver of need for informed consent, along with a careful procedure to avoid selection bias when enrolling patients into the database. Data on 144 eligible patients with T4 tumors were collected (T4, N0-1, M0-1; mean age 49.7 years; 65{\%} female; 88{\%} papillary cancer). All had received 131I remnant ablation following TSH stimulation with rhTSH or thyroid hormone withdrawal (THW) since January 2000 (rhTSH n=74, THW n=70). The primary endpoint was based on evaluation of diagnostic radioiodine scan thyroid bed uptake more than six months after the ablation procedure, while stimulated serum Tg was a secondary endpoint. Safety was evaluated within 30 days after rhTSH or 131I. Results: Successful ablation judged by scan was achieved in 65/70 (92.9{\%}) of rhTSH and in 61/67 (91.0{\%}) of THW patients; the success rates were comparable, since noninferiority criteria were met. Although some patients in the initial cohort had tumor in cervical nodes and metastases, considering all evaluable patients regardless of various serum anti-Tg antibody assessments, the stimulated Tg was 30 IU/mL were excluded, the stimulated Tg was",
author = "Peter Bartenstein and Calabuig, {Elisa Caballero} and Maini, {Carlo Ludovico} and Renzo Mazzarotto and {De Fuentes}, {M. Angustias Muros} and Thorsten Petrich and Rodrigues, {Fernando Jos{\'e} Cravo} and {Vallejo Casas}, {Juan Antonio} and Federica Vianello and Michela Basso and Balaguer, {Marcelino G{\'o}mez} and Alexander Haug and Fabio Monari and Vaň{\'o}, {Raquel S{\'a}nchez} and Rosa Sciuto and James Magner",
year = "2014",
month = "3",
day = "1",
doi = "10.1089/thy.2013.0157",
language = "English",
volume = "24",
pages = "480--487",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal

AU - Bartenstein, Peter

AU - Calabuig, Elisa Caballero

AU - Maini, Carlo Ludovico

AU - Mazzarotto, Renzo

AU - De Fuentes, M. Angustias Muros

AU - Petrich, Thorsten

AU - Rodrigues, Fernando José Cravo

AU - Vallejo Casas, Juan Antonio

AU - Vianello, Federica

AU - Basso, Michela

AU - Balaguer, Marcelino Gómez

AU - Haug, Alexander

AU - Monari, Fabio

AU - Vaňó, Raquel Sánchez

AU - Sciuto, Rosa

AU - Magner, James

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Background: Few data exist on using thyrotropin alfa (recombinant human thyroid-stimulating hormone [rhTSH]) with radioiodine for thyroid remnant ablation of patients who have T4 primary tumors (invasion beyond the thyroid capsule). Methods: A retrospective chart review protocol at nine centers in Europe was set up with special waiver of need for informed consent, along with a careful procedure to avoid selection bias when enrolling patients into the database. Data on 144 eligible patients with T4 tumors were collected (T4, N0-1, M0-1; mean age 49.7 years; 65% female; 88% papillary cancer). All had received 131I remnant ablation following TSH stimulation with rhTSH or thyroid hormone withdrawal (THW) since January 2000 (rhTSH n=74, THW n=70). The primary endpoint was based on evaluation of diagnostic radioiodine scan thyroid bed uptake more than six months after the ablation procedure, while stimulated serum Tg was a secondary endpoint. Safety was evaluated within 30 days after rhTSH or 131I. Results: Successful ablation judged by scan was achieved in 65/70 (92.9%) of rhTSH and in 61/67 (91.0%) of THW patients; the success rates were comparable, since noninferiority criteria were met. Although some patients in the initial cohort had tumor in cervical nodes and metastases, considering all evaluable patients regardless of various serum anti-Tg antibody assessments, the stimulated Tg was 30 IU/mL were excluded, the stimulated Tg was

AB - Background: Few data exist on using thyrotropin alfa (recombinant human thyroid-stimulating hormone [rhTSH]) with radioiodine for thyroid remnant ablation of patients who have T4 primary tumors (invasion beyond the thyroid capsule). Methods: A retrospective chart review protocol at nine centers in Europe was set up with special waiver of need for informed consent, along with a careful procedure to avoid selection bias when enrolling patients into the database. Data on 144 eligible patients with T4 tumors were collected (T4, N0-1, M0-1; mean age 49.7 years; 65% female; 88% papillary cancer). All had received 131I remnant ablation following TSH stimulation with rhTSH or thyroid hormone withdrawal (THW) since January 2000 (rhTSH n=74, THW n=70). The primary endpoint was based on evaluation of diagnostic radioiodine scan thyroid bed uptake more than six months after the ablation procedure, while stimulated serum Tg was a secondary endpoint. Safety was evaluated within 30 days after rhTSH or 131I. Results: Successful ablation judged by scan was achieved in 65/70 (92.9%) of rhTSH and in 61/67 (91.0%) of THW patients; the success rates were comparable, since noninferiority criteria were met. Although some patients in the initial cohort had tumor in cervical nodes and metastases, considering all evaluable patients regardless of various serum anti-Tg antibody assessments, the stimulated Tg was 30 IU/mL were excluded, the stimulated Tg was

UR - http://www.scopus.com/inward/record.url?scp=84896794595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896794595&partnerID=8YFLogxK

U2 - 10.1089/thy.2013.0157

DO - 10.1089/thy.2013.0157

M3 - Article

C2 - 24040896

AN - SCOPUS:84896794595

VL - 24

SP - 480

EP - 487

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 3

ER -